Drug · CHEMBL1024
IFOSFAMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. IFOSFAMIDE. Drugs and targets, record CHEMBL1024. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1024
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Ifosfamida, Isocyclophosphamide, Isophosphamide, MJF 9325, MJF-9325, NSC-109724, Z-4942, Z4942
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 130 diseases, from ATC, DailyMed and PMDA
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases130
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 130Source Open Targets
See all 130 diseasesTrials416
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00134030 | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma | Phase 3 | 1,334 | 2023-06-07 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | Phase 3 | 637 | 2020-08-10 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | Phase 3 | 588 | 2017-10-06 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT00345865 | Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | Phase 2 | 473 | 2020-07-14 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Phase 3 | 312 | 2022-07-01 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT00302003 | Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | Phase 3 | 287 | 2017-02-09 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | Phase 3 | 263 | 2021-06-07 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT01602666 | Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors | Phase 2 | 262 | 2020-12-16 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 187 | 2018-03-12 | ifosfamide | Its name | ClinicalTrials.gov |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | Phase 2 | 175 | 2017-07-28 | ifosfamide | Its name | ClinicalTrials.gov |
1 to 10 of 416
See all 416 trialsComparisons in its trials59
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: deaths from any cause | 160 of 272 | 160 of 267 | 539 | NCT00954174 | Trial comparisons |
| Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: serious adverse events | 80 of 268 | 68 of 247 | 515 | NCT00954174 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): deaths from any cause | 61 of 145 | 67 of 150 | 295 | NCT02306161 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): serious adverse events | 3 of 145 | 45 of 150 | 295 | NCT02306161 | Trial comparisons |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) vs Stratum 2 Localized Germinoma: deaths from any cause | 13 of 107 | 2 of 137 | 244 | NCT01602666 | Trial comparisons |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) vs Stratum 2 Localized Germinoma: serious adverse events | 5 of 107 | 1 of 137 | 244 | NCT01602666 | Trial comparisons |
| Arm I vs Arm II: deaths from any cause | 61 of 98 | 66 of 105 | 203 | NCT00104676 | Trial comparisons |
| Arm I vs Arm II: serious adverse events | 37 of 98 | 58 of 105 | 203 | NCT00104676 | Trial comparisons |
| IMC-A12 vs Temozolomide: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | 89 of 96 | 61 of 70 | 166 | NCT01055314 | Trial comparisons |
| Group 1 (Chemotherapy, Radiation Therapy, Cixutumumab) vs Group 2 (Chemotherapy, Radiation Therapy, Temozolomide): serious adverse events | 79 of 96 | 40 of 70 | 166 | NCT01055314 | Trial comparisons |
1 to 10 of 59
See all 59 comparisons in its trialsPapers from its trials285
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 1 | 1 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1024
GET https://conductscience.org/api/drugs/v1/CHEMBL1024/diseases?page=2